Medical treatment for prostate cancer
Reading File
Finding Sources
Searching PubMed
"prostate cancer"[MeSH Terms] AND "therapeutics"[MeSH Terms]
Reading File
Finding Sources
Searching PubMed
"prostatic neoplasms"[MeSH Terms] AND treatment
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content to produce a detailed, well-organized answer. Let me synthesize this into a full response.
Medical Treatment of Prostate Cancer
Treatment is determined primarily by disease stage, risk stratification (PSA level, Gleason/Grade Group, clinical T stage), patient life expectancy, and patient preference. The major treatment categories are: observation/surveillance, local curative therapy, hormonal therapy, chemotherapy, targeted/immunotherapy, and bone-directed therapy.
1. Risk Stratification
Before selecting treatment, prostate cancer is categorized as:
| Risk Group | PSA | Gleason Grade Group | Clinical Stage |
|---|---|---|---|
| Very Low / Low | <10 ng/mL | GG1 (Gleason 6) | T1–T2a |
| Intermediate | 10–20 ng/mL | GG2–3 (Gleason 7) | T2b–T2c |
| High / Very High | >20 ng/mL | GG4–5 (Gleason 8–10) | T3–T4 |
| Metastatic | Any | Any | N1 or M1 |
Germline genetic testing (BRCA1/2, ATM, MLH1/MSH2) is recommended in high-risk, very-high-risk, regional, or metastatic disease and in men with a family history of epithelial cancers. — Goldman-Cecil Medicine
2. Localized Disease
2a. Watchful Waiting / Active Surveillance
- Watchful waiting: observation without intent to cure; preferred when life expectancy < 10 years or significant comorbidity.
- Active surveillance (AS): PSA every 6 months, digital rectal exam annually, repeat biopsy every 12 months (or guided by MRI), and consideration of MRI spectroscopy.
- Endorsed by AUA, ASTRO, SUO, and NCCN as the preferred management for very-low-risk and the preferable option for most low-risk localized disease.
- MRI-targeted biopsy is increasingly incorporated into AS algorithms to improve candidate selection and detect occult upgrading.
- Men with intermediate- or high-risk disease should be strongly discouraged from surveillance. — Campbell Walsh Wein Urology, p. 4626–4627
2b. Radical Prostatectomy (RP)
- Indicated for clinically localized disease with life expectancy > 10 years.
- Robot-assisted or laparoscopic RP is now preferred over open surgery: shorter hospital stay, less blood loss, fewer complications, lower rates of incontinence and erectile dysfunction.
- Pelvic lymph node dissection (PLND) is added when nodal involvement risk is high; extended PLND removes nodes from the external iliac, pelvic side wall, bladder wall, pelvic floor, and internal iliac artery.
- Nerve-sparing technique preserves erectile function in appropriately selected patients. — Goldman-Cecil Medicine, p. 2109
2c. Radiation Therapy
External Beam Radiation Therapy (EBRT):
- Delivers photon or proton beams; 3D image-guided/IMRT (intensity-modulated) is standard to minimize dose to bladder and rectum.
- Hypofractionation (19 fractions of 3.4 Gy or 7 fractions of 4.1 Gy) is increasingly used and equivalent in efficacy to conventional fractionation.
- Proton therapy is highly conformal but does not improve clinical outcomes vs photons despite higher cost.
Brachytherapy:
- Permanent low-dose-rate (LDR) seed implantation or temporary high-dose-rate (HDR) interstitial implants.
- Used alone for early-stage, low-risk disease, or combined with EBRT for higher-risk disease.
2d. Focal/Ablative Therapies
Focal ablation (cryotherapy, HIFU, radiofrequency ablation) targeted to the index lesion is an option for selected localized cancer or locally recurrent hormone-resistant disease. These are considered less established than RP or radiation. — Hinman's Atlas of Urologic Surgery; Campbell Walsh Urology
3. High-Risk Localized and Locally Advanced Disease (Stage III)
- Stage IIIA: Androgen-deprivation therapy (ADT) + EBRT or brachytherapy; or radical prostatectomy with PLND.
- Stage IIIB, IIIC, IVA, IVB: EBRT ± brachytherapy + ADT ± docetaxel; or radical prostatectomy with PLND.
- Long-term ADT (2–3 years) combined with radiation significantly improves survival over radiation alone in high-risk disease.
4. Androgen Deprivation Therapy (ADT)
ADT is the cornerstone of treatment for locally advanced and metastatic disease. It works by suppressing testosterone to castrate levels.
Methods:
| Type | Agents |
|---|---|
| GnRH agonists | Leuprolide, goserelin, triptorelin (initially cause testosterone surge — "flare") |
| GnRH antagonists | Degarelix, relugolix (no flare; oral option available) |
| Orchiectomy | Bilateral surgical castration — gold standard historically |
| Antiandrogens | Bicalutamide, flutamide (block AR; used with GnRH agonists) |
Side effects require proactive management: hot flashes, loss of libido/erectile dysfunction, osteoporosis, metabolic syndrome, cardiovascular risk, cognitive effects, and fatigue. Collaboration with cardiology, endocrinology, and orthopedics is often needed; bone health requires supplemental vitamin D, calcium, and bisphosphonates. — Goldman-Cecil Medicine, p. 2110
5. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The standard of care has shifted from ADT alone to ADT + intensification with one of the following:
| Agent | Class | Notes |
|---|---|---|
| Docetaxel | Taxane chemotherapy | CHAARTED/STAMPEDE trials; high-volume disease |
| Abiraterone | CYP17A1 inhibitor | Blocks androgen synthesis; with prednisone |
| Enzalutamide | AR antagonist (2nd-gen) | ARCHES/ENZAMET trials |
| Apalutamide | AR antagonist (2nd-gen) | TITAN trial |
| Darolutamide | AR antagonist (2nd-gen) | ARASENS trial; better CNS safety profile |
— Goldman-Cecil Medicine (Table 186-3)
6. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Once disease progresses despite castrate testosterone levels, multiple salvage options exist:
Chemotherapy
- Docetaxel (75 mg/m² q3 weeks) — first-line; survival benefit in TAX327 trial
- Cabazitaxel — second-line taxane after docetaxel failure
Novel Hormonal Agents
- Abiraterone acetate (with prednisone) — COU-AA-301 trial (post-docetaxel); COU-AA-302 (pre-docetaxel)
- Enzalutamide — AFFIRM trial (post-docetaxel); PREVAIL (pre-docetaxel)
- Darolutamide — favorable CNS penetrance, fewer drug interactions
Immunotherapy
- Sipuleucel-T (Provenge) — autologous dendritic cell vaccine; FDA-approved for asymptomatic/minimally symptomatic mCRPC; modest ~4-month OS benefit (IMPACT trial)
- Pembrolizumab — anti-PD-1; approved for TMB-high or MSI-high solid tumors including prostate cancer
PARP Inhibitors (for DNA repair-deficient tumors)
- Olaparib — approved for BRCA1/2-mutated mCRPC (PROfound trial)
- Rucaparib — approved for BRCA1/2 or ATM mutations
Bone-Directed Therapy
- Radium-223 (Xofigo) — alpha-emitting radiopharmaceutical; targets bone metastases; OS benefit in ALSYMPCA trial; reduces skeletal-related events
- Zoledronic acid / Denosumab — prevent skeletal complications in bone-metastatic disease
Radioligand Therapy (Theranostics)
- ¹⁷⁷Lu-PSMA-617 (Lutetium vipivotide tetraxetan / Pluvicto) — targets PSMA-expressing cells; approved for PSMA-positive mCRPC following prior ARPI and docetaxel (VISION trial); requires positive PSMA PET/CT (e.g., ⁶⁸Ga-PSMA-11). — Goldman-Cecil Medicine, p. 2110
7. Biochemical (PSA) Relapse
After definitive local treatment, rising PSA indicates recurrence:
| Option | Setting |
|---|---|
| Observation | Slow PSA rise, limited life expectancy |
| Salvage EBRT | After radical prostatectomy; early salvage preferred |
| Salvage RP | After radiation (high morbidity) |
| ADT | Rapidly rising PSA, short doubling time |
PSA doubling time < 6 months and short interval to biochemical recurrence predict worse outcomes and usually prompt earlier treatment.
8. Summary by Stage
| Stage | Primary Treatment Options |
|---|---|
| I | Observation, active surveillance, EBRT/brachytherapy, radical prostatectomy ± PLND |
| II | Active surveillance, EBRT/brachytherapy, radical prostatectomy ± PLND |
| IIIA | ADT + EBRT/brachytherapy; radical prostatectomy + PLND |
| IIIB–IVB | EBRT ± brachytherapy + ADT ± docetaxel; RP + PLND |
| PSA relapse | Observation, salvage RT, salvage RP, ADT |
| mHSPC | ADT + docetaxel / abiraterone / enzalutamide / apalutamide / darolutamide |
| mCRPC | ADT + docetaxel/cabazitaxel, abiraterone, enzalutamide, darolutamide, sipuleucel-T, olaparib, rucaparib, radium-223, pembrolizumab, ¹⁷⁷Lu-PSMA-617 |
Sources: Goldman-Cecil Medicine (Table 186-3, pp. 2109–2110); Campbell Walsh Wein Urology (pp. 4626–4689)
Recent Evidence Updates
The 2024 EAU Guidelines on Prostate Cancer (Part I) (Cornford et al., Eur Urol 2024; PMID 38614820) updated screening, diagnosis, and local treatment recommendations. Part II (Tilki et al., Eur Urol 2024; PMID 38688773) covers relapsing and metastatic disease management — both represent the most current systematic evidence synthesis. A 2024 meta-analysis in JAMA Oncology (El-Taji et al.; PMID 38842801) highlights increased cardiovascular risk with androgen receptor signaling inhibitors in advanced prostate cancer — an important safety consideration when selecting AR-targeted agents in patients with pre-existing cardiovascular disease.
Waht is finasteride given in larien
Reading File
Finding Sources
Finding Sources
Searching the Web
finasteride "larien" OR "laryngeal" indication use
Finding Sources
Finding Sources
Reading File
"Larien" is almost certainly a misspelling of "alopecia" (hair loss). The textbook content makes this clear. Here's the answer:
Finasteride in Alopecia ("larien" = alopecia)
"Larien" appears to be a misspelling of alopecia. Finasteride is used specifically in androgenetic alopecia (male pattern hair loss).
Mechanism
Finasteride is a 5α-reductase inhibitor. It blocks the conversion of testosterone → dihydrotestosterone (DHT) — the androgen responsible for androgenetic alopecia in genetically predisposed men. — Katzung's Basic & Clinical Pharmacology, 16th ed.
Dose
- 1 mg/day orally (brand name: Propecia)
- Distinct from the 5 mg dose used for benign prostatic hyperplasia (Proscar)
Efficacy
- Promotes hair growth and prevents further hair loss in a significant proportion of men.
- Requires at least 3–6 months of treatment before visible benefit (hair growth/loss prevention is a slow process).
- Continuous use is necessary to sustain benefit — stopping finasteride reverses the effect.
Important Limitations
- No evidence supports its use in women with androgenetic alopecia.
- Contraindicated in pregnant women — even handling crushed tablets is dangerous due to the risk of hypospadias developing in a male fetus.
Side Effects
| Side Effect | Notes |
|---|---|
| Decreased libido | Resolves in most men who continue therapy; resolves in all who stop |
| Ejaculation disorders | Reversible |
| Erectile dysfunction | Reversible |
| Orthostatic hypotension | Less common |
| Dizziness | Less common |
In summary: Finasteride 1 mg/day is given in androgenetic (male pattern) alopecia to reduce scalp DHT levels, slow hair loss, and promote regrowth — with treatment needing to be continued long-term to maintain the effect.
Why fenasteride given in. Patient of prostate
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Excellent — comprehensive textbook content retrieved. Here is a complete answer:
Why is Finasteride Given in Prostate Disease?
Finasteride is given in Benign Prostatic Hyperplasia (BPH) — enlargement of the prostate — not in prostate cancer directly. Here is why:
The Core Problem: DHT Drives Prostate Growth
The prostate gland is highly sensitive to dihydrotestosterone (DHT), a potent androgen derived from testosterone. DHT stimulates prostate cell proliferation, causing the gland to enlarge and compress the urethra, leading to:
- Difficulty urinating / weak stream
- Urinary frequency and urgency
- Incomplete bladder emptying
Mechanism of Finasteride
Finasteride is a 5α-reductase inhibitor. It blocks the enzyme 5α-reductase, which converts testosterone → DHT.
Testosterone ──[5α-reductase]──► DHT (potent androgen)
BLOCKED by
FINASTERIDE
By reducing DHT levels:
- The prostate gland shrinks (by ~30%)
- Urinary flow improves
- Symptoms of BPH decrease
— Smith & Tanagho's General Urology, 19th ed.; Lippincott Pharmacology
Dose in Prostate Disease
- Finasteride 5 mg/day orally (brand: Proscar)
- Takes 6–12 months to achieve maximum symptom relief (unlike α-blockers which work in 7–10 days)
- Only effective in men with enlarged prostates (>40 cm³) — no benefit in small glands
Important Clinical Notes
| Point | Detail |
|---|---|
| Onset | 6–12 months for full effect |
| Prostate size reduction | ~30% |
| PSA effect | Reduces serum PSA by ~50% — must be accounted for when interpreting PSA for cancer screening |
| Often combined with | An α-blocker (e.g., tamsulosin) for faster symptom relief while finasteride takes effect |
Side Effects
- Decreased libido
- Decreased ejaculate volume
- Erectile dysfunction (impotence)
- Gynecomastia
- Teratogenic — pregnant women must not handle the tablets (risk of genital birth defects in male fetus)
Finasteride in Prostate Cancer Prevention
As noted in the previous session, finasteride and dutasteride (5α-reductase inhibitors) also reduce the risk of developing prostate cancer. However, neither is FDA-approved for cancer prevention because early studies raised concerns about increasing the risk of higher-grade tumors (though more recent evidence has questioned this concern). — Goldman-Cecil Medicine
In summary: Finasteride is given in BPH because DHT is the primary driver of prostate enlargement. By blocking its production, finasteride shrinks the gland and relieves urinary obstruction symptoms.
Duta steride
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of dutasteride, with a direct comparison to finasteride:
Dutasteride
Drug Class
Dual 5α-reductase inhibitor (5ARI) — brand name Avodart
Key Difference from Finasteride
This is the most important distinction:
| Feature | Finasteride | Dutasteride |
|---|---|---|
| Isozyme inhibited | Type 2 only | Types 1 AND 2 (dual) |
| DHT reduction (serum) | ~70% | ~90% |
| Potency | Less potent | More potent |
| Dose | 5 mg/day (BPH), 1 mg (alopecia) | 0.5 mg/day |
| Half-life | 6–16 hours | ~5 weeks (long-acting) |
Because dutasteride inhibits both type 1 and type 2 5α-reductase, it produces a greater and more complete reduction in DHT than finasteride. — Campbell Walsh Wein Urology; Lippincott Pharmacology
Mechanism of Action
Testosterone ──[5α-reductase Type 1 & 2]──► DHT
BOTH BLOCKED by
DUTASTERIDE
DHT is the androgen that drives prostate gland growth. By blocking both isoforms of the enzyme, dutasteride:
- Reduces serum DHT by ~90.2%
- Shrinks prostate volume by ~25–30% over 24 months
- Improves urinary flow rate
Indications
- Benign Prostatic Hyperplasia (BPH) — primary indication
- Androgenetic alopecia (male pattern hair loss) — like finasteride
- Prostate cancer risk reduction (investigated in the REDUCE trial)
Clinical Evidence (REDUCE Trial)
In the REDUCE trial, dutasteride vs. placebo in men with BPH and prior negative prostate biopsy showed:
- 57% reduction in risk of acute urinary retention (AUR)
- 48% reduction in need for BPH-related surgery
- Reduced incidence of diagnosed prostate cancer vs. placebo — Campbell Walsh Wein Urology, p. 4421
Dosing
| Indication | Dose |
|---|---|
| BPH | 0.5 mg orally once daily |
| Combination with tamsulosin | Available as fixed-dose combination (Jalyn) |
- Takes 6–12 months for full symptom relief
- Only effective when prostate is enlarged (>30 cm³)
Pharmacokinetics
- Absorption: Not affected by food
- Protein binding: Highly protein bound
- Metabolism: CYP450 system
- Half-life: Terminal half-life ~5 weeks (steady-state reached after ~6 months) — much longer than finasteride's 6–16 hours
- PSA effect: Reduces serum PSA by ~50% — must be corrected for when screening for prostate cancer
Side Effects
| Side Effect | Notes |
|---|---|
| Erectile dysfunction | ~6% at 1 year; rate drops after 2 years |
| Decreased libido | ~3.7% at 1 year |
| Decreased ejaculate volume | Common |
| Gynecomastia | Less common |
| Oligospermia | Noted |
| Teratogenic | Women must NOT handle tablets — risk of genital birth defects in male fetus |
| Depressive symptoms | FDA safety review 2011 — possible risk |
Dutasteride vs. Finasteride — Summary
| Finasteride | Dutasteride | |
|---|---|---|
| Isoform | Type 2 only | Types 1 + 2 |
| DHT suppression | ~70% | ~90% |
| Dose (BPH) | 5 mg/day | 0.5 mg/day |
| Half-life | Short (6–16 h) | Very long (~5 weeks) |
| Combination product | No | Yes (with tamsulosin = Jalyn) |
| Alopecia use | Yes (1 mg) | Yes (off-label) |
| Teratogenic | Yes | Yes |
Bottom line: Dutasteride is essentially a more potent, longer-acting version of finasteride, inhibiting both isoforms of 5α-reductase to achieve superior DHT suppression — making it more effective in men with larger prostates and offering a convenient once-daily, low-dose regimen.
Other drug given in bph
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have everything needed for a comprehensive answer on all BPH drugs.
All Drugs Used in BPH (Benign Prostatic Hyperplasia)
Three main pharmacological classes are used to treat BPH, plus combination strategies:
Class 1: α1-Adrenergic Antagonists (Alpha Blockers)
Fastest-acting class — symptom relief within 7–10 days
These are the first-line drugs for BPH. They work by relaxing smooth muscle in the prostate and bladder neck, improving urine flow.
Mechanism
α1 receptors in the prostate (α1A) and vasculature (α1B) are blocked → prostate smooth muscle relaxes → improved urinary flow.
Drugs & Doses
| Drug | Selectivity | Dose |
|---|---|---|
| Tamsulosin | α1A selective (prostate-specific) | 0.4–0.8 mg/day |
| Silodosin | α1A selective | 8 mg/day |
| Alfuzosin | α1A + α1B (non-selective) | 10 mg/day |
| Doxazosin | α1A + α1B (non-selective) | 4–8 mg/day |
| Terazosin | α1A + α1B (non-selective) | 5–10 mg/day |
Selectivity Matters
- Tamsulosin & Silodosin → more selective for prostate → less orthostatic hypotension, but more retrograde ejaculation
- Doxazosin, Terazosin, Alfuzosin → block vasculature too → lower blood pressure (require dose titration), more dizziness
Side Effects
- Orthostatic hypotension, dizziness (especially non-selective)
- Retrograde ejaculation / anejaculation (especially tamsulosin, silodosin)
- Headache, fatigue, rhinitis
- Floppy iris syndrome — warn patients before cataract surgery
— Lippincott Illustrated Reviews Pharmacology; Smith & Tanagho's General Urology
Class 2: 5α-Reductase Inhibitors (5ARIs)
Slower onset — take 6–12 months; only effective in enlarged prostate
As discussed in detail previously:
| Drug | Isoform | Dose | DHT reduction |
|---|---|---|---|
| Finasteride | Type 2 only | 5 mg/day | ~70% |
| Dutasteride | Types 1 & 2 (dual) | 0.5 mg/day | ~90% |
- Shrink prostate by ~25–30%
- Reduce risk of acute urinary retention (AUR) and BPH surgery
- Reduce PSA by ~50% (important for cancer screening interpretation)
- Teratogenic — no handling by pregnant women
Class 3: Phosphodiesterase-5 (PDE-5) Inhibitor
Tadalafil is the only PDE-5 inhibitor FDA-approved for BPH
Mechanism
PDE-5 is present in the prostate and bladder smooth muscle. Tadalafil inhibits PDE-5 → increases cGMP → smooth muscle vasodilation and relaxation → improves LUTS (lower urinary tract symptoms).
| Drug | Dose for BPH |
|---|---|
| Tadalafil (Cialis) | 5 mg once daily |
Evidence
- Reduces IPSS (symptom score) by ~3.8 points vs. 1.7 with placebo
- Particularly useful in men with BPH + erectile dysfunction (treats both simultaneously)
- Can be combined with α-blockers for added benefit
Note: Sildenafil and vardenafil are not approved for BPH (only tadalafil is). — Lippincott Pharmacology; Campbell Walsh Urology
Combination Therapy
| Combination | Rationale | Evidence |
|---|---|---|
| α-blocker + 5ARI | Fast relief (α-blocker) + long-term shrinkage (5ARI) | MTOPS & CombAT trials — superior to monotherapy in men with large prostates |
| Dutasteride + Tamsulosin | Available as fixed-dose combo: Jalyn | Reduces AUR and surgery risk more than either alone |
| α-blocker + Tadalafil | Additive smooth muscle relaxation | Useful in BPH + ED |
| 5ARI + anticholinergic | For BPH + overactive bladder (OAB) symptoms | Tolterodine + dutasteride studied |
Additional / Off-label Agents
| Drug | Class | Notes |
|---|---|---|
| Anticholinergics (tolterodine, solifenacin) | Muscarinic antagonists | Used when storage symptoms (urgency, frequency) predominate; caution in urinary retention |
| Mirabegron | β3-adrenergic agonist | For OAB component of BPH/LUTS; safer in elderly |
| Phytotherapy (Saw palmetto / Serenoa repens) | Plant extract | Weak/inconsistent evidence; not endorsed by AUA guidelines |
Quick Summary Comparison
| Class | Drug Examples | Onset | Effect | Best For |
|---|---|---|---|---|
| α-blockers | Tamsulosin, Doxazosin | Days | Relax muscle | Symptom relief, all prostate sizes |
| 5ARIs | Finasteride, Dutasteride | 6–12 months | Shrink gland | Large prostate (>40 cm³) |
| PDE-5i | Tadalafil | Weeks | Relax muscle | BPH + ED |
| Combination | Jalyn (dutasteride + tamsulosin) | Immediate + long-term | Both | Large prostate, high progression risk |
Sources: Lippincott Illustrated Reviews Pharmacology; Smith & Tanagho's General Urology, 19th ed.; Campbell Walsh Wein Urology
This is a shared conversation. Sign in to Orris to start your own chat.